Physician profile
Noor S Sachdev
NPI 1710141072
$282,196.73
in general payments reported to CMS, 2019-2025
76 companies · $74K in 2025
The $74K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $18K · 2021: $50K · 2022: $38K · 2023: $40K · 2024: $40K · 2025: $74K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $88K · Consulting Fee: $26K · Food and Beverage: $17K · Travel and Lodging: $15K · Honoraria: $7,250 · Education: $351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $88,342.50 |
| Consulting Fee | $25,932.50 |
| Food and Beverage | $16,537.96 |
| Travel and Lodging | $15,026.92 |
| Honoraria | $7,250.00 |
| Education | $351.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $117,760.23 | 2019-2025 | Ubrelvy, Qulipta, Botox |
| Argenx US, INC. | $31,119.92 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Amgen INC. | $25,306.49 | 2019-2025 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $20,858.52 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Biohaven Pharmaceuticals, INC. | $17,151.52 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $13,960.50 | 2019-2025 | Ultomiris, Soliris |
| Lundbeck LLC | $12,339.79 | 2019-2025 | Vyepti, Rexulti |
| Lilly USA, LLC | $9,532.28 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Sarepta Therapeutics, INC. | $6,455.87 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $5,665.03 | 2022 | |
| Allergan, INC. | $2,739.69 | 2019-2022 | |
| Ucb, INC. | $2,077.96 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Eisai INC. | $1,712.55 | 2019-2025 | |
| Biogen, INC. | $1,603.86 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Sk Life Science, INC. | $1,460.86 | 2020-2025 | Xcopri |
Show all 76 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noor Sachdev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.